现实世界维护阶段持续在乌斯特基努马布和阿达利努马布在性结肠炎
Maryia Zhdanava1, Sumesh Kachroo2, Aditi Shah1
1Analysis Group, Inc, Montréal, QC, Canada.
Patient preference and adherence
|April 15, 2024
概括
乌斯特基努马布在性结肠炎 (UC) 患者的现实世界持久性比阿达利穆马布更高. 这包括在没有皮质类固醇和单疗时更好的持久性,无论是生物原始还是生物经验丰富的个体.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 生物疗法,包括抗TNF药物和ustekinumab等新药,是UC治疗的主要支柱.
- 关于这些疗法的比较持久性的真实数据对于临床决策至关重要.
研究的目的:
- 为了比较乌斯特基努马布 (抗IL-12/23) 与阿达利努马布 (抗TNF) 在UC的成年患者中的实际持续时间.
- 通过先前的生物暴露来分层评估持久性 (生物原始与生物经验).
- 评估在没有皮质类固醇和单疗时的持续性.
主要方法:
- 一项描述性,回顾性队列研究,使用大型医疗保健索赔数据集.
- 确定了在2019年10月至2021年8月期间开始使用乌斯特基努马布或阿达利努马布的患者.
- 卡普兰-梅尔分析用于评估12个月的持续性,无皮质类固醇的持续性和单一治疗的持续性.
主要成果:
- 乌斯特基努马布在12个月的持久性比阿达利穆马布在生物原始患者 (75.5%对50.5%) 和生物经验 (72.3%对56.9%) 的UC患者中都比数值上更高.
- 在两个小组中,在没有皮质类固醇的情况下,在ustekinumab治疗中观察到更高的持续率.
- 在单一治疗期间,乌斯特基努马布的持续性也比阿达利努马布的数量更高.
结论:
- 乌斯特基努马布在12个月的维护后开始时,在UC患者中,与阿达利穆马布相比,在现实世界中的持久性在数量上表现出优异.
- 这些发现延伸到不使用皮质类固醇和单疗时的持续性.
- 乌斯特基努马布代表了UC的潜在更持久的生物治疗选择.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
01:21Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
173
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
173